Skip to main content

Drug Interactions between Botox and fesoterodine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fesoterodine onabotulinumtoxinA

Applies to: fesoterodine and Botox (onabotulinumtoxinA)

MONITOR: Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders. Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.

MANAGEMENT: Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.

References

  1. "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals PROD
  2. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc PROD
  3. "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc PROD
  4. "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals (2022):
  5. "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc. (2022):
  6. "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc. 1 (2022):
  7. "Product Information. Letybo (letibotulinumtoxinA)." CROMA Australia Pty Ltd 1 (2022):
  8. "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics (2024):
View all 8 references

Switch to consumer interaction data

Drug and food interactions

Moderate

fesoterodine food

Applies to: fesoterodine

MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.

MANAGEMENT: Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.

References

  1. "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group (2008):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer